Skip to main content

Table 3 Prevalence of persistent pain, according to the treatments performed

From: Prevalence of persistent pain after breast cancer treatment by detection mode among participants in population-based screening programs

 

Persistent paina

 
 

N (%)

P-value

Surgery (n = 1043)

  

 Radical (n = 224)

27 (12.1)

0.693

 Conservative (n = 819)

91 (11.1)

 

Axillary treatmentb (n = 983)

 

<0.01

 Only SLNB (n = 268)

18 (6.7)

 

 ALND (n = 715)

98 (13.7)

 

Neoadjuvant therapy (n = 1045)

 

0.090

 No (n = 936)

111 (11.9)

 

 Yes (n = 109)

7 (6.4)

 

Adjuvant therapy post-surgery (n = 1039)

 

1

 No (n = 26)

3 (11.5)

 

 Yes (n = 1013)

115 (11.4)

 

Chemotherapy (n = 1018)

 

<0.01

 No (n = 513)

43 (8.4)

 

 Yes (n = 505)

73 (14.5)

 

Radiotherapy (n = 998)

 

0.457

 No (n = 155)

15 (9.7)

 

 Yes (n = 843)

99 (11.7)

 

Hormone therapy (n = 1019)

 

0.328

 No (n = 219)

29 (13.2)

 

 Yes (n = 800)

87 (10.9)

 

Her2 treatment (n = 1028)

 

0.790

 No (n = 979)

112 (11.4)

 

 Yes (n = 49)

5 (10.2)

 
  1. aPercentages are computed as follows: number of women with persistent pain divided by the total number of women for each category
  2. bSLNB: sentinel lymph node biopsy. In this category only women with SLNB performed were included. ALND: axillary lymph node dissection. This category includes women with only ALND performed and women with SLNB and ALND